Thermo Fisher Scientific Inc. (TMO) SEC Filing 10-K Annual report for the fiscal year ending Thursday, December 31, 2015

Earnings Press Release
10-K Annual Report
10-K YoY Changes
Thermo Fisher Scientific Inc.
Ticker: TMO CIK: 97745

Exhibit 99.1

News



FOR IMMEDIATE RELEASE
Media Contact Information: Karen Kirkwood	Investor Contact Information: Ken Apicerno
Phone: 781-622-1306	Phone: 781-622-1294
E-mail: karen.kirkwood@thermofisher.com	E-mail: ken.apicerno@thermofisher.com
Website: www.thermofisher.com

Thermo Fisher Scientific Reports Record Fourth Quarter and Full Year 2015 Results

WALTHAM, Mass. (January 28, 2016) - Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2015.

Fourth Quarter and Full Year 2015 Highlights


•	Grew fourth quarter adjusted earnings per share (EPS) by 7% to $2.12 and full year adjusted EPS by 6% to $7.39.


•	Increased fourth quarter revenue by 4% to $4.65 billion.


•	Expanded fourth quarter adjusted operating margin by 40 basis points to 23.2%.


•	Launched significant new products in 2015 for research, clinical and applied markets, highlighted by the QuantStudio 3 and 5 qPCR systems, Orbitrap Fusion Lumos Tribrid mass spectrometer and the Ion S5 and S5 XL next-generation sequencing instruments.


•	Leveraged increasing scale in Asia-Pacific and emerging markets to deliver strong growth, led by outstanding performance in China and significant contributions from India and South Korea.


•	Successfully integrated the Life Technologies acquisition, which strengthened our customer value proposition and accelerated growth.


•	In 2015, deployed nearly $700 million to expand our bioproduction and laboratory chemicals offerings through acquisitions of Advanced Scientifics, Inc. and Alfa Aesar; also repurchased $500 million of stock.


•	Reduced debt by approximately $2.0 billion in 2015 and achieved target leverage ratio.


•	After year end, announced agreement to acquire Affymetrix for $1.3 billion to strengthen leadership in biosciences and genetic analysis.

Adjusted EPS, adjusted operating income, adjusted operating margin and free cash flow are non-GAAP measures that exclude certain items detailed later in this press release under the heading “Use of Non-GAAP Financial Measures.”

The following information was filed by Thermo Fisher Scientific Inc. (TMO) on Thursday, January 28, 2016 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Thermo Fisher Scientific Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Thermo Fisher Scientific Inc..

Continue

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/97745/000009774516000043/tmo201510k.htm